Skip to main content
SpringerLink
Log in

Update of the Treatment Guidelines for Well-Differentiated Thyroid Cancer

  • Chapter
  • First Online:
Surgical Endocrinopathies

  • 887 Accesses

Abstract

The goals of clinical practice guidelines are to improve patient care by providing consensus on stage-specific therapies, reduce the use of unnecessary or harmful interventions, and to maximize the chance of treatment benefit at accepted societal costs. The American Thyroid Association (ATA) has published three prior versions of differentiated thyroid cancer (DTC) recommendation guidelines, and is set to release a fourth iteration in the upcoming year. The volume of research that has been performed in the field of thyroid cancer over the past decade has been immense. Therefore, in order to continue to maintain clinical excellence and state-of-the-art practice patterns, guidelines must be frequently updated and controversies perpetually reexamined. In this chapter, we discuss some relevant controversies and we examine some of the more significant updates in the treatment of well-differentiated thyroid cancer, as described by the ATA.

Editors’ Note: This chapter and the chapter “Well-differentiated Thyroid Cancer” by Dr. Yip are excellent companion pieces. We suggest reading them together to appreciate the many nuances of therapy for thyroid nodules and thyroid cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 149.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Howlander N, et al. SEER cancer statistics review, 1975–2011. National Cancer Institute. 2013. http://seer.cancer.gov/csr/1975_2011. Posted to the SEER web site, April 2014.

  2. Irani S, et al. Evaluating clinical practice guidelines developed for the management of thyroid nodules and thyroid cancers and assessing the reliability and validity of the AGREE instrument. J Eval Clin Pract. 2011;17(4):729–36.

    Article  PubMed  Google Scholar 

  3. Carling T, et al. American Thyroid Association design and feasibility of a prospective randomized controlled trial of prophylactic central lymph node dissection for papillary thyroid carcinoma. Thyroid. 2012;22(3):237–44.

    Article  PubMed  Google Scholar 

  4. U.S. Preventive Services Task Force Grade Definitions. USPTF. http://www.uspreventiveservicestaskforce.org/uspstf/grades.htm. Accessed 1 May 2014.

  5. Davis L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006;295:2164–67

    Article  Google Scholar 

  6. Singer P, et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. Arch Intern Med. 1996;156:2165–72.

    Article  CAS  PubMed  Google Scholar 

  7. Cooper DS, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16(2):109–42.

    Article  PubMed  Google Scholar 

  8. Cooper D, et al. Revised American Thyroid Association Management Guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–214.

    Article  PubMed  Google Scholar 

  9. Grant CS. Papillary thyroid cancer: strategies for optimal individualized surgical management. Clin Ther. 2014;36:1117–26.

    Article  PubMed  Google Scholar 

  10. Boelaert K, et al. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J Clin Endocrinol Metab. 2006;91(11):4295–301.

    Article  CAS  PubMed  Google Scholar 

  11. NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma. Version 2. 2013. http://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf. Accessed 1 May 2014.

  12. Gharib H, et al. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyrois Association Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules. Endocr Pract. 2010;16(1):1–43.

    Article  PubMed  Google Scholar 

  13. Perros P, et al. Guidelines for the management of thyroid cancer. 2nd ed. British Thyroid Association, Royal College of Physicians; 2007.

    Google Scholar 

  14. Conzo G, et al. The current status of lymph node dissection in the treatment of papillary thyroid cancer. A literature review. Clin Ter. 2013;164(4):343–6.

    Google Scholar 

  15. Kouvaraki MA, et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery. 2003;134(6):946–54.

    Article  PubMed  Google Scholar 

  16. O’Connell K, et al. The utility of routine preoperative cervical ultrasonography in patients undergoing thyroidectomy for differentiated thyroid cancer. Surgery. 2013;154(4):697–701.

    Article  PubMed  Google Scholar 

  17. Stulak JM, et al. Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Arch Surg. 2006;141(5):489–94.

    Article  PubMed  Google Scholar 

  18. Marshall CL, et al. Routine pre-operative ultrasonography for papillary thyroid cancer: effects on cervical recurrence. Surgery. 2009;146(6):1063–72.

    Article  PubMed  Google Scholar 

  19. Chaikhoutdinov I, et al. Incidental thyroid nodules: incidence, evaluation, and outcome. Otolaryngol Head Neck Surg. 2014;150: 939–42.

    Article  PubMed  Google Scholar 

  20. Liebeskind A, et al. Rates of malignancy in incidentally discovered thyroid nodules evaluated with sonography and fine-needle aspiration. J Ultrasound Med. 2005;24:629–34.

    PubMed  Google Scholar 

  21. Sung JY, et al. Diagnostic accuracy of fine-needle aspiration versus core-needle biopsy for the diagnosis of thyroid malignancy in a clinical cohort. Eur Radiol. 2012;22(7):1564–72.

    Article  PubMed  Google Scholar 

  22. Cibas ES, Ali SZ. The Bethesda system for reporting thyroid cytopathology. Am J Clin Pathol. 2009;132(5):658–65.

    Article  PubMed  Google Scholar 

  23. Ahmadieh H, Azar ST. Controversies in the management and followup of differentiated thyroid cancer: beyond the guidelines. J Thyroid Res. 2012; Epub ahead of print.

    Google Scholar 

  24. Yip L, et al. Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery. 2009;146(6): 1215–23.

    Article  PubMed  Google Scholar 

  25. Alexander EK, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med. 2012;367(8): 705–15.

    Article  CAS  PubMed  Google Scholar 

  26. Alexander EK, et al. Multicenter clinical experience with the Afirma gene expression classifier. J Clin Endocrinol Metab. 2014;99(1):119–25.

    Article  CAS  PubMed  Google Scholar 

  27. McIver B, et al. An independent study of a gene expression classifier (Afirma™) in the evaluation of cytologically indeterminate thyroid nodules. J Clin Endocrinol Metab. 2014; Epub ahead of print.

    Google Scholar 

  28. Tuttle RM, et al. Clinical features associated with an increased risk of thyroid malignancy in patients with folicular neoplasm by fine-needle aspiration. Thyroid. 1998;8(5):377–83.

    Article  CAS  PubMed  Google Scholar 

  29. Tamez-Pérez HE, et al. Nondiagnostic thyroid fine needle aspiration cytology: outcome in surgical treatment. Rev Invest Clin. 2007;59(3):180–3.

    PubMed  Google Scholar 

  30. Bilimoria KY, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 2007;246(3):375–81; discussion 381–74.

    Article  PubMed Central  PubMed  Google Scholar 

  31. Pelizzo MR, et al. High prevalence of occult papillary thyroid carcinoma in a surgical series for benign thyroid disease. Tumori. 1990;76(3):255–7.

    CAS  PubMed  Google Scholar 

  32. Yu XM, et al. Current treatment of papillary thyroid microcarcinoma. Adv Surg. 2012;46:191–203.

    Article  PubMed  Google Scholar 

  33. Ito Y, et al. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid. 2014;24(1):27–34.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  34. Wang TS, et al. Papillary thyroid microcarcinoma: an over-treated malignancy? World J Surg. 2014; Epub ahead of print.

    Google Scholar 

  35. Carty SE, et al. Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid. 2009;19(11):1153–8.

    Article  PubMed  Google Scholar 

  36. Stack BC, et al. American thyroid association consensus review and statement regarding the anatomy, terminology, and rationale for lateral neck dissection in differentiated thyroid cancer. Thyroid. 2012;22(5):501–8.

    Article  PubMed  Google Scholar 

  37. Davidson HC, et al. Papillary thyroid cancer: controversies in the management of neck metastasis. Laryngoscope. 2008;118(12): 2161–5.

    Article  PubMed  Google Scholar 

  38. Mazzaferri EL, et al. The pros and cons of prophylactic central compartment lymph node dissection for papillary thyroid carcinoma. Thyroid. 2009;19(7):683–9.

    Article  PubMed  Google Scholar 

  39. Lee CR, et al. Lobectomy and prophylactic central neck dissection for papillary thyroid microcarcinoma: do involved lymph nodes mandate completion thyroidectomy? World J Surg. 2014;38(4): 872–7.

    Article  PubMed  Google Scholar 

  40. Oltmann SC, et al. Radioactive iodine remnant uptake after completion thyroidectomy: not such a complete cancer operation. Ann Surg Oncol. 2014;21(4):1379–83.

    Article  PubMed Central  PubMed  Google Scholar 

  41. Luster M, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35(10): 1941–59.

    Article  CAS  PubMed  Google Scholar 

  42. Zaman MU, et al. Controversies about radioactive iodine-131 remnant ablation in low risk thyroid cancers: are we near a consensus? Asian Pac J Cancer Prev. 2013;14(11):6209–13.

    Article  PubMed  Google Scholar 

  43. Hugo J, et al. recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence. Thyroid. 2012;22(10):1007–15.

    Article  CAS  PubMed  Google Scholar 

  44. Tu J, et al. Recombinant human thyrotropin-aided versus thyroid hormone withdrawal-aided radioiodine treatment for differentiated thyroid cancer after total thyroidectomy: a meta-analysis. Radiother Oncol. 2014;110(1):25–30.

    Article  CAS  PubMed  Google Scholar 

  45. Tuttle RM, et al. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med. 2008;49(5):764–70.

    Article  PubMed  Google Scholar 

  46. Castagna MG, et al. Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. J Clin Endocrinol Metab. 2008;93(1):76–81.

    Article  CAS  PubMed  Google Scholar 

  47. Kloos RT, Mazzaferri EL. A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab. 2005;90(9):5047–57.

    Article  CAS  PubMed  Google Scholar 

  48. Tuttle RM, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid. 2010;20(12):1341–9.

    Article  CAS  PubMed  Google Scholar 

  49. Boi F, et al. The diagnostic value for differentiated thyroid carcinoma metastases of thyroglobulin (Tg) measurement in washout fluid from fine-needle aspiration biopsy of neck lymph nodes is maintained in the presence of circulating anti-Tg antibodies. J Clin Endocrinol Metab. 2006;91(4):1364–9.

    Article  CAS  PubMed  Google Scholar 

  50. Snozek CL, et al. Serum thyroglobulin, high-resolution ultrasound, and lymph node thyroglobulin in diagnosis of differentiated thyroid carcinoma nodal metastases. J Clin Endocrinol Metab. 2007;92(11):4278–81.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Division of Surgical Oncology, Medical College of Wisconsin, Milwaukee, WI, USA

    Jason A. Glenn MD

  2. Division of Surgical Oncology, Section of Endocrine Surgery, Medical College of Wisconsin, 9200 W. Wisconsin Avenue, 53226, Milwaukee, WI, USA

    Assoc Prof Tracy S. Wang MD, MPH

Authors
  1. Jason A. Glenn MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Assoc Prof Tracy S. Wang MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tracy S. Wang MD, MPH .

Editor information

Editors and Affiliations

  1. Divisions of General Surgery and Surgical Oncology, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada

    Janice L. Pasieka

  2. Department of Surgery, Columbia University Medical Center, New York, New York, USA

    James A. Lee

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Glenn, J., Wang, T. (2015). Update of the Treatment Guidelines for Well-Differentiated Thyroid Cancer. In: Pasieka, J., Lee, J. (eds) Surgical Endocrinopathies. Springer, Cham. https://doi.org/10.1007/978-3-319-13662-2_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-13662-2_17

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-13661-5

  • Online ISBN: 978-3-319-13662-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation